Literature DB >> 19047286

Sensitivity to input variability of the Adjuvant! Online breast cancer prognostic model.

Elissa M Ozanne1, Dejana Braithwaite, Karen Sepucha, Dan Moore, Laura Esserman, Jeffrey Belkora.   

Abstract

PURPOSE: Adjuvant! Online (www.adjuvantonline.org) is a software model that predicts the benefit of adjuvant therapy for women with early-stage breast cancer. The model has been validated, is widely consulted, and has been shown to influence patient choices in the clinical setting. Adjuvant! requires the clinician to input patient age, tumor size, grade, hormone receptor status, number of positive lymph nodes, and comorbidity level. Because comorbidity is strongly and independently associated with survival, this study tested the hypothesis that Adjuvant! predictions would be sensitive to comorbidity inputs.
METHODS: Investigators used single-variable deterministic sensitivity analysis to evaluate the effect of varying each input of the model independently for three representative case examples based on National Comprehensive Cancer Network guidelines (NCCN). The main outcome of interest was 10-year mortality prediction.
RESULTS: The analyses show that Adjuvant!'s 10-year mortality predictions are most sensitive to patients' comorbidity levels and the extent of nodal involvement for the cases, particularly among older women. Comorbidity was the most influential input except in younger women, aged 40 years.
CONCLUSION: The Adjuvant! model is sensitive to patient comorbidity, and impact on the model outputs are significant enough that they are likely to affect physician recommendations and patients' treatment choices. For example, incorrect assessments of comorbidities could lead physicians to overtreat or undertreat a patient who is in a gray zone relative to the NCCN guidelines. These results point to the importance of accurately assessing comorbidities in patients with breast cancer when using Adjuvant! and highlight the need for a standardized process of comorbidity ascertainment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19047286     DOI: 10.1200/JCO.2008.17.3914

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  10 in total

1.  Counterpoint: sowing the seeds of standardized care to reap better patient outcomes.

Authors:  Joseph O Jacobson
Journal:  J Oncol Pract       Date:  2012-05-29       Impact factor: 3.840

2.  Oncologists' recommendations for adjuvant therapy in hormone receptor-positive breast cancer patients of varying age and health status.

Authors:  Arash Naeim; F Lennie Wong; Sumanta K Pal; Arti Hurria
Journal:  Clin Breast Cancer       Date:  2010-04       Impact factor: 3.225

Review 3.  Advancement of prognostic models in breast cancer: a narrative review.

Authors:  Ningning Min; Yufan Wei; Yiqiong Zheng; Xiru Li
Journal:  Gland Surg       Date:  2021-09

4.  Biomarkers in Breast Cancer - An Update.

Authors:  M Schmidt; P A Fasching; M W Beckmann; H Kölbl
Journal:  Geburtshilfe Frauenheilkd       Date:  2012-09       Impact factor: 2.915

5.  Factors associated with receipt of breast cancer adjuvant chemotherapy in a diverse population-based sample.

Authors:  Jennifer J Griggs; Sarah T Hawley; John J Graff; Ann S Hamilton; Reshma Jagsi; Nancy K Janz; Mahasin S Mujahid; Christopher R Friese; Barbara Salem; Paul H Abrahamse; Steven J Katz
Journal:  J Clin Oncol       Date:  2012-08-06       Impact factor: 44.544

6.  Risk assessment, disease prevention and personalised treatments in breast cancer: is clinically qualified integrative approach in the horizon?

Authors:  Olga Golubnitschaja; Kristina Yeghiazaryan; Vincenzo Costigliola; Daniela Trog; Michael Braun; Manuel Debald; Walther Kuhn; Hans H Schild
Journal:  EPMA J       Date:  2013-02-19       Impact factor: 6.543

Review 7.  Gene signatures of breast cancer progression and metastasis.

Authors:  David I Rodenhiser; Joseph D Andrews; Theodore A Vandenberg; Ann F Chambers
Journal:  Breast Cancer Res       Date:  2011-01-24       Impact factor: 6.466

8.  Prognostic utility of the breast cancer index and comparison to Adjuvant! Online in a clinical case series of early breast cancer.

Authors:  Rachel C Jankowitz; Kristine Cooper; Mark G Erlander; Xiao-Jun Ma; Nicole C Kesty; Hongying Li; Mamatha Chivukula; Adam Brufsky
Journal:  Breast Cancer Res       Date:  2011-10-14       Impact factor: 6.466

9.  Assessment of the contribution of the IHC4+C score to decision making in clinical practice in early breast cancer.

Authors:  S Barton; L Zabaglo; R A'Hern; N Turner; T Ferguson; S O'Neill; M Hills; I Smith; M Dowsett
Journal:  Br J Cancer       Date:  2012-04-24       Impact factor: 7.640

10.  Pilot Study of a Web-based Decision Tool on Post-operative Use of Radioactive Iodine.

Authors:  Shrujal S Baxi; Rachel Kurtzman; Anne Eaton; Eliza Dewey; Craig Bickford; Stephanie Fish; Leonard Wartofsky; R Michael Tuttle
Journal:  Eur Endocrinol       Date:  2017-04-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.